🇺🇸 FDA
Patent

US 11071778

Combination product for use in tumor vaccination

granted A61KA61K2039/54A61K2039/545

Quick answer

US patent 11071778 (Combination product for use in tumor vaccination) held by DCPRIME B.V. expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DCPRIME B.V.
Grant date
Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/54, A61K2039/545, A61K2039/585, A61K2039/6037